Carl Zeiss Meditec (CZMWY) Stock Price, News & Analysis

Company Overview

Carl Zeiss Meditec AG is a global medical technology company specializing in ophthalmic and microsurgical solutions. As a subsidiary of the Carl Zeiss Group, the company focuses on the development, manufacturing and distribution of devices for eye care professionals, including diagnostic imaging systems, surgical microscopes and laser platforms. Its products are designed to support vision screening, cataract, glaucoma and refractive procedures, as well as a range of other ophthalmic treatments.

The company’s product portfolio includes optical coherence tomography (OCT) systems for high-resolution imaging of the retina, phacoemulsification units for cataract removal, intraocular lenses (IOLs) for implantation, and femtosecond lasers used in minimally invasive corneal and refractive surgery. In microsurgery, Carl Zeiss Meditec offers advanced surgical microscopes and visualization tools that enhance precision in neurosurgical, dental and plastic surgery settings. Many of its platforms integrate digital workflows, enabling seamless connectivity between preoperative diagnostics and operative guidance systems.

Founded on the legacy of Carl Zeiss dating back to 1846 in Jena, Germany, Carl Zeiss Meditec AG was established as a publicly traded entity in 2002 to consolidate the group’s medical technology activities. Headquartered in Jena and Munich, the company has cultivated a broad international presence, serving healthcare providers in Europe, North America, Asia-Pacific, Latin America and other regions. Its global network of sales offices, distributors and service centers ensures local support and training for clinicians and technicians.

Leadership at Carl Zeiss Meditec is committed to advancing innovative technologies that address unmet needs in eye care and surgery. Under the guidance of CEO Dr. Ludwin Monz, the company continues to invest in research and development, partnerships and digital health initiatives aimed at improving patient outcomes and streamlining clinical workflows. Carl Zeiss Meditec’s strategic priorities include expanding its diagnostic portfolio, enhancing surgical capabilities and driving adoption of data-driven solutions across ophthalmic and microsurgical markets.

Key Stats

• Today's Range: $59.08 to $60.68
• 50-Day Range: $58.95 to $71.73
• 52-Week Range: $46.13 to $80.09
• Volume: 3,627 shs
• Average Volume: 4,156 shs
• Market Capitalization: N/A
• P/E Ratio: 65.22
• Dividend Yield: 0.50%
• Price Target: N/A
• Consensus Rating: Hold

Carl Zeiss Meditec Stock Analysis - MarketRank™

Carl Zeiss Meditec scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Carl Zeiss Meditec.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Carl Zeiss Meditec is 65.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carl Zeiss Meditec is 65.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.01.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Carl Zeiss Meditec has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carl Zeiss Meditec has recently increased by 107.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Carl Zeiss Meditec pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Carl Zeiss Meditec does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Carl Zeiss Meditec is 32.64%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Carl Zeiss Meditec has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Carl Zeiss Meditec has recently increased by 107.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Carl Zeiss Meditec this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carl Zeiss Meditec insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Carl Zeiss Meditec is held by institutions.

CZMWY Stock Analysis - Frequently Asked Questions

How have CZMWY shares performed this year?

Carl Zeiss Meditec's stock was trading at $47.50 on January 1st, 2025. Since then, CZMWY shares have increased by 26.3% and is now trading at $60.00.

How do I buy shares of Carl Zeiss Meditec?

Shares of CZMWY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 8/07/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CZMWY
• CIK: N/A
• Web: www.zeiss.com
• Phone: 493641220115
• Fax: N/A
• Employees: 4,823
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 64.64
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A